Xcyte Pulls Xcellerated T Cells from Clinical Trail for CLL, Per FDA Request

[Guest guest]

[Disappointing delay. I hope it's nothing serious.]

Xcyte Therapies, Inc. Announces Withdrawal Of Protocol for Phase

II/III Clinical Trial in Chronic Lymphocytic Leukemia and Potential

Delay in Trial Initiation

Wednesday February 2, 4:05 pm ET

SEATTLE--(BUSINESS WIRE)--Feb. 2, 2005--Xcyte Therapies, Inc.

( " Xcyte " , the " Company " ) (Nasdaq:XCYT - News) announced today that it

has withdrawn its submission to the FDA of the clinical protocol for

a planned Phase II/III trial of Xcellerated T Cells in chronic

lymphocytic leukemia. The FDA requested the withdrawal to allow

additional discussion of the design of the trial. The protocol will

be resubmitted to the FDA as a draft protocol. Xcyte expects that

these actions and additional discussions may result in a delay in the

initiation of the trial beyond the second quarter of 2005.

" We have been working closely with the FDA on the design of this

trial since our End of Phase II meeting in September 2004, " said Ron

Berenson, M.D., President and Chief Executive Officer of Xcyte

Therapies. " We intend to work diligently with the FDA to resolve the

remaining issues as quickly as possible. "

Xcyte is scheduled to meet with the FDA in mid-February to discuss

the chemistry, manufacturing and controls submission related to this

trial and to the planned transfer of the Company's manufacturing

operations to its newly completed facility in Bothell, Washington.